PRAME Expression and Melanoma In Situ Margin Assessment.

Am J DermatopatholJun 22, 2026 (epub)
Case ReportDermatologyOpen access

Thomas N Helm, Charlene Lam, Bohdan Zoshchuk et al.

✦ AI-curated · Sources linked

Case in brief

A case of melanoma in situ of the lentigo maligna type on chronically sun-damaged skin presented a diagnostic challenge in margin assessment. Despite the use of PRAME immunohistochemistry to delineate subclinical spread, the extent of the melanoma was found to exceed the clinically visible borders, complicating the determination of clear margins.

Diagnostic / clinical pearl

PRAME immunohistochemistry can aid in assessing margins for melanoma in situ, but clinicians should be aware that the disease may extend beyond visible borders.

Source

PubMed · PMID 42331601Free full text on PubMed Central

Published in Am J Dermatopathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.